Trial Profile

An Open Label, Phase Ia/Ib Dose Finding Study With BI 894999 Orally Administered Once a Day in Patients With Advanced Malignancies, With Repeated Administration in Patients With Clinical Benefit

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 18 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BI 894999 (Primary)
Indications Adenocarcinoma; Colorectal cancer; Diffuse large B cell lymphoma; Prostate cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man
Sponsors Boehringer Ingelheim; Boehringer Ingelheim GmbH International; Boehringer Ingelheim Pharma KG

Most Recent Events

16 Dec 2021 According to European Clinical Trials Database, this trial has been discontinued in Denmark.
16 Dec 2021 This trial has been completed in Germany, according to European Clinical Trials Database.
03 Dec 2021 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com